Mesoblast Limited secures exclusive global rights to CAR-MSC technology from Mayo Clinic to enhance targeted cell therapies for inflammatory and autoimmune diseases.
Written By: Karthik Teja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
Mesoblast Limited has secured an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform aimed at enhancing its mesenchymal stromal cell (MSC) therapies. The company plans to integrate engineered CAR constructs into its MSC portfolio to improve target specificity and strengthen immunomodulatory and tissue-regenerative effects.
Mesoblast’s MSC-based therapies target inflammatory diseases by leveraging the cells’ inherent ability to home to damaged tissues and regulate immune responses. Incorporating CAR technology is intended to enhance this targeting precision, potentially increasing therapeutic potency.
Scientific Basis and Target Indications
The CAR-MSC platform is based on research conducted at Mayo Clinic and published in Nature Biomedical Engineering, where engineered CAR-MSCs demonstrated improved tissue-specific targeting in inflammatory and autoimmune conditions.
This approach creates opportunities to advance therapies for gastrointestinal inflammatory diseases such as ulcerative colitis and Crohn’s disease, where enhanced homing to inflamed bowel tissue may improve efficacy. The company also plans to develop CAR-MSCs engineered to express CD19 to target B cell–driven autoimmune diseases, including lupus nephritis.
Transaction and Collaboration
Mesoblast obtained exclusive global rights to the CAR-MSC intellectual property through the acquisition of a startup established to develop the technology. The transaction was completed through the issuance of ASX-listed ordinary shares.
Under the agreement, Mayo Clinic will provide in-kind support, including contributions to Good Manufacturing Practice (GMP) manufacturing activities, to support further development.
Leadership View
Chief Executive Silviu Itescu stated that integrating CAR technology supports the company’s strategy to expand its leadership in allogeneic cellular medicines and enables development of therapies with greater efficacy and broader clinical applications.
References
Mesoblast Acquires Chimeric Antigen Receptor (Car) Platform Technology for Precision-Enhanced Cell Products, 15 April 2026, 223699d4-0d65-42f7-9530-f5fe7131a89a
Sirpilla O et al, Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression. Nat Biomed Eng. 2024 Apr;8(4):443-460. Epub 2024 Apr 1. PMID: 38561490; PMCID: PMC12080371, https://doi.org/10.1038/s41551-024-01195-6
About the Writer
Karthik Teja Macharla, PharmD is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.
